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12-Lipoxygenase is increased in glucose-stimulated mesangial The molecular and cellular mechanisms responsible
cells and in experimental diabetic nephropathy. for diabetic nephropathy remain incompletely resolved.
Background. Arachidonic acid-derived 12-lipoxygenase While studies indicate involvement of hyperglycemia via(12-LO) products have potent growth and chemotactic prop-
the stimulation of growth factor-induced cellular hyper-erties. The present studies examined whether 12-LO and fi-
trophy [1, 2], increased production of extracellular matrixbronectin are induced in cultured rat mesangial cells (MCs)
exposed to high glucose and whether they are expressed in protein [3–6] and decreased production of matrix-
experimental diabetic nephropathy. degrading proteinases [7, 8], the underlying pathways
Methods. To determine the effect of high glucose on MC mediating these processes have been explored less well.12-LO mRNA and protein expression, rat MCs were incubated
The interaction of various growth factors with theirwith RPMI medium containing 100 (NG) or 450 mg/dL glucose
cell surface receptors leads to signaling events and the(HG). For animal studies, rats were injected with diluent (con-
trol) or streptozotocin. The latter were left untreated (DM) activation of several phospholipases, which in turn can
or treated with insulin (DM 1 I). At sacrifice after four months, lead to the release of arachidonic acid [9, 10]. Arachi-
GAPDH, 12-LO, and fibronectin mRNA were measured by
donic acid can be metabolized by at least three differentcompetitive reverse transcription-polymerase chain reaction
pathways: the cyclooxygenase pathway to prostaglandins(RT-PCR) in microdissected glomeruli (G). Renal sections
were semiquantitatively scored (0 to 41) for diabetic changes and thromboxane; the lipoxygenase pathway to lipoxy-
and for 12-LO and fibronectin by immunohistochemistry. genase (LO) products such as 5-, 12-, and 15-hydroxy-
Results. 12-LO mRNA expression in MC exposed to HG eicosatetraenoic acids (HETEs) and leukotrienes; and
(12.71 6 1.17 attm/mL) and DM G (1.78 6 0.65 3 1023 attm/
the cytochrome P-450 epoxygenase pathway to epoxidesglomerulus) was significantly higher than those of MCs in NG
and other products [11]. Exposure to or stimulated re-media (6.71 6 0.78 attm/mL) and control G (0.34 6 0.12 3
1023 attm/glomerulus, P , 0.005), respectively. Western blot lease of 12-lipoxygenase (12-LO) products plays a key
revealed a 1.7- and a 2.8-fold increase in MC and G 12-LO role in cellular hypertrophic and mitogenic responses to
protein expression, respectively (P , 0.05). The immunohisto- growth factors [12–14]. In vascular smooth muscle cells,chemistry score for G 12-LO and diabetic nephropathy score
high glucose, angiotensin II, and platelet-derived growthwas significantly greater in DM and DM 1 I than controls.
factor-BB, all molecules that activate protein kinase CMC and G GAPDH mRNA remained unchanged.
Conclusions. In MCs exposed to HG and in diabetic rat (PKC) and are purported to mediate diabetic nephropa-
glomeruli, increments in 12-LO mRNA and protein are associ- thy also stimulate a dose-dependent increases in 12-LO
ated with changes modeling diabetic nephropathy. These find- activity and expression [13, 14]. Indeed, the downstreamings suggest a role for the 12-LO pathway in the pathogenesis
effects of high-glucose concentrations and angiotensinof diabetic nephropathy.
II in vascular smooth muscle cells, including hypertrophy
and extracellular matrix synthesis, are substantially abro-
gated by pharmacological inhibition of 12-LO [13], dem-
onstrating the criticality of the lipoxygenase pathwayKey words: glomerular microdissection, extracellular matrix, renal glo-
meruli, cell hypertrophy. in mediating the effects of these molecules. Exogenous
provision of 12-HETE, a major product of the 12-LOReceived for publication July 27, 2000
pathway, leads to PKC translocation from the cytosoland in revised form October 23, 2000
Accepted for publication October 26, 2000 to membrane fractions and also activates specific PKC
isoforms in adrenal glomerulosa cells, demonstrating theÓ 2001 by the International Society of Nephrology
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capacity for PKC activation by lipoxygenase products FCS for 24 hours. Thereafter, medium was changed to
[15]. In addition, 12-LO products, particularly under NG or HG medium with 0.2% BSA and was harvested
high-glucose conditions, stimulate extracellular matrix after 24 hours.
synthesis by vascular smooth muscle cells [16].
AnimalsIn kidney, the 5-LO pathway has demonstrated patho-
genetic importance in experimental immune-mediated All animal studies were conducted under an approved
glomerular disease [17, 18], but it has not been evaluated protocol. Thirty male Sprague-Dawley rats weighing 220
in diabetic nephropathy. Evidence suggests that in glo- to 250 g were studied. Eight were injected with diluent
meruli, 12- and 15-LO activity predominate, leading to [control (C)], and 22 were injected with 65 mg/kg strepto-
the synthesis of 12- and 15-HETE [19, 20]. Rat tissues zotocin intraperitoneally. Blood glucose levels were
mainly express a leukocyte-type 12-LO [21], and Katoh measured on the third day after streptozotocin injection
et al have identified and partially sequenced a leukocyte- to confirm the development of diabetes. Diabetic rats
type 12-LO/15-LO from rat glomeruli [22]. Moreover, a were then randomly assigned to two groups. One group,
high ambient glucose concentration has been shown to comprised of eight rats, was treated with 2 U/day of
induce arachidonic acid release in mesangial cells (MCs), Humulin (DM 1 I; Ultralente; Eli Lilly Co., Indianapo-
along with cyclooxygenase product synthesis, and PKC lis, IN, USA), and the remaining 14 diabetic rats were left
activation [23], but in the former study, the LO pathway untreated (DM). The rats were housed in a temperature-
was not assessed. Since MCs are similar in origin and controlled room and were given free access to water and
behavior to vascular smooth muscle cells, this study was standard laboratory chow during the four-month study
performed to evaluate whether 12-LO mRNA and pro- period.
tein are increased in glucose-stimulated MCs and in ex- Serum glucose and creatinine and 24-hour urinary al-
perimental diabetic nephropathy. Furthermore, studies bumin were measured monthly. Blood glucose was mea-
were also performed to determine whether fibronectin sured by glucometer, and serum creatinine was measured
production is also increased in association with the acti- with a Creatinine Analyzer 2 (Beckman Instruments,
vation of the 12-LO pathway. Inc., Fullerton, CA, USA). Twenty-four–hour urinary
albumin excretion was determined by ELISA (Nephrat
II; Exocell, Inc., Philadelphia, PA, USA). Body weightsMETHODS
were measured weekly, and kidney weights were mea-Mesangial cell culture
sured at the time of sacrifice.
Renal glomeruli were isolated from male Sprague-
Dawley rats (Charles River Laboratories, Wilmington, Microdissection and total RNA extraction
MA, USA) weighing 250 to 300 g. Kidneys were removed.
Glomerular microdissection was performed as pre-Glomeruli were isolated by differential sieving, and iso-
viously described [25, 26], with minor modifications. Fiftylated glomeruli were incubated in collagenase and tryp-
glomeruli from the renal cortex were microdissected atsin-ethylenediaminetetraacetic acid (EDTA) (GIBCO
48C in a solution of vanadyl ribonucleoside complex andLaboratories, Bethesda, MA, USA) as described pre-
were rinsed and transferred to a tube with RNAse inhibi-viously [24]. The identification of mesangial cells (MCs)
tor. Total RNA was extracted by the addition of 100 mLwas performed by their characteristic stellate appearance
of RNA STAT-60 reagent (Tel-Test, Inc., Friendswood,in culture and was confirmed by immunofluorescent mi-
TX, USA) to the glomeruli, followed by glomerular lysiscroscopy for the presence of actin, myosin, and Thy-1
by freezing and thawing three times. Another 700 mL ofantigen and the absence of factor VIII and cytokeratin
RNA STAT-60 reagent were added, and the mixture(Synbiotics, San Diego, CA, USA). MCs were maintained
was vortexed and stored for five minutes at room temper-in RPMI 1640 (Mediatech Inc., Herndon, VA, USA)
ature. Four hundred microliters of chloroform weresupplemented with l-glutamine, HEPES 7 mmol/L, and
added, and the mixture shaken vigorously for 30 seconds.10% fetal calf serum (FCS; Hyclone Laboratories, Lo-
After three minutes, the mixture was centrifuged atgan, UT, USA) and were incubated at 378C in humidified
12,000 3 g for 15 minutes at 48C, and the upper aqueous5% CO2 in air.
phase containing the extracted RNA was transferred toTo determine the effect of high glucose on MC 12-LO
a new tube. RNA was precipitated from the aqueousmRNA and protein expression, rat MCs were plated in
phase by 400 mL isopropanol and pelleted with centrifu-100 mm dishes for mRNA experiments and 60 mm dishes
gation at 12,000 3 g for 30 minutes at 48C. The RNAfor Western blot analysis and were incubated with RPMI
precipitate was washed with 70% ice-cold ethanol, driedmedium containing 100 mg/dL (NG) or 450 mg/dL (HG)
using Speed Vac, and dissolved in DEPC-treated dis-glucose with 10% FCS, allowed to grow for five days to
tilled water. RNA from tubulointerstitial tissue and MCsconfluence, and serum starved with NG or HG medium
containing 0.2% bovine serum albumin (BSA) and 0.4% was extracted similarly. Glomerular, tubulointerstitial,
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and MC RNA yield and quality were assessed based on minute; and (3) 12-LO, 42 cycles, denaturation at 958C
for one minute, annealing at 608C for one minute, andspectrophotometric measures at 260 and 280 OD.
extension at 728C for one minute. For competitive PCR
Reverse transcription of MC 12-LO, the first PCR was done by 35 cycles, and
the nested PCR was done by 32 cycles with 0.1 mL of theFirst-strand cDNA was made by utilizing a Boehringer
Mannheim cDNA synthesis kit (Boehringer Mannheim first PCR product under the same conditions as described
previously in this article. Initial heating at 958C for nineGmbH, Mannheim, Germany). Total RNA from 50 glo-
meruli was reversed transcribed using 10 mmol/L random minutes and final extension at 728C for seven minutes
were performed for all PCRs. The reverse transcription-hexanucleotide primer, 1 mmol/L dNTP, 8 mmol/L
MgCl2, 30 mmol/L KCl, 50 mmol/L Tris-HCl, pH 8.5, PCR (RT-PCR) products were separated by electropho-
resis, the band densities were analyzed by laser densitom-0.2 mmol/L dithiothreitol, 25 U RNAse inhibitor, and
40 U AMV reverse transcriptase. The mixture was incu- etry (Helena Laboratories, Beaumont, TX, USA). The
values log transformed, and a log-linear regression analy-bated at 308C for 10 minutes and 428C for one hour,
followed by inactivation of enzyme at 998C for five min- sis was performed against the competitor concentration
for each PCR tube. The quantity of cDNA in the testutes. Tubulointerstitial RNA, aliquoted in amounts
equivalent to that of the glomerular samples, and 2 mg sample was defined as the amount at which the competi-
tor and wild-type optical density bands were equal.of MC RNA from each plate were similarly reverse tran-
scribed.
Western blot analysis
Quantitative competitive polymerase chain reaction Rat glomeruli isolated using sieves and MCs harvested
from plates were lyzed in sodium dodecyl sulfate (SDS)Competitor cDNAs were used as internal standards
in quantitative polymerase chain reaction (PCR). Each sample buffer [2% SDS, 10 mmol/L Tris-HCl, pH 6.8,
10% (vol/vol) glycerol]. Lysate was centrifuged atcompetitor was designed to contain the same base pair
sequence as the target cDNA that would allow efficient 10,000 3 g for 10 minutes at 48C, and the supernatant
was stored at 2708C until all rats were sacrificed. Proteinpriming, but had a portion deleted so that the competitor
PCR-generated fragment could be easily distinguished concentrations were determined with a Bio-Rad kit (Bio-
Rad Laboratories, Inc., Hercules, CA, USA). Aliquotselectrophoretically by size. Thus, to quantitate the rat
GAPDH, leukocyte-type 12-LO [27], and fibronectin mRNA of 50 mg protein were treated with Laemmli sample
buffer, then heated at 1008C for five minutes, and electro-content of each sample, a competitive PCR technique
was applied. The primers used for rat GAPDH, 12-LO, phoresed 50 mg/lane in an 8% acrylamide denaturing
SDS-polyacrylamide gel. Proteins were transferred toand fibronectin amplification were as follows: GAPDH
sense, 59-GACAAGATGGTGAAGGTCGG-39, anti- Hybond-ECL membrane (Amersham Life Science, Inc.,
Arlington Heights, IL, USA) using a Hoeffer semidrysense 59-CATGGACTGTGGTCATGAGC-39; 12-LO sense
59-TGGGGCAACTGGAAGG-39, antisense 59-AGAG blotting apparatus (Hoeffer Instruments, San Francisco,
CA, USA). The membrane was incubated in blockingCGCTTCAGCACCAT-39; and fibronectin sense 59-GCA
AGCCTGAACCTGAAGAGACC-39, antisense 59-CCT buffer A [1 3 phosphate-buffered saline (PBS), 0.1%
Tween-20, and 8% nonfat milk] for one hour at roomGGTGTCCTGATCATTGCATC-39. The competitive
PCR for 12-LO of MC was performed using nested PCR, temperature and then incubated overnight at 48C with
a polyclonal antibody raised in rabbits to a specific leuko-and the sense and antisense primers for the first PCR were
59-GGGCAGAAGCATCCTGAGCC-39 and 59-GGAG cyte 12-LO peptide with sequence homology to amino
acids 39 to 55 of porcine leukocyte 12-LO [14, 28]. TheTAGACCCAGTTTTGGG-39, respectively. cDNA from
one tenth of a glomerulus or 0.5 ng RNA of MC per membrane was washed once for 15 minutes and twice
for five minutes in 1 3 PBS with 0.1% Tween-20 andreaction tube was used for GAPDH and fibronectin and
one half of a glomerulus or 25 ng RNA of MC for 12-LO. incubated in buffer A with horseradish peroxidase-
linked sheep anti-mouse IgG (Amersham) at 1:1000 dilu-PCR was performed using the test or wild-type cDNA,
Taq-Gold polymerase (1 U for GAPDH and fibronectin; tion. The washes were repeated, and the membrane de-
veloped with chemiluminescent agent (ECL; Amersham1.5 U for 12-LO), 20 mmol/L dNTP, sense and antisense
primers (20 pmol for GAPDH and fibronectin; 30 pmol Life Science, Inc.).
for 12-LO), and serial dilutions of competitor in a volume
Pathologyof 50 mL containing 1 3 PCR buffer. The PCR conditions
were as follows: (1) GAPDH, 35 cycles, denaturation at Coronal slices of kidney for routine light microscopy
were placed into alcoholic Bouin’s solution and were958C for one minute, annealing at 628C for one minute,
and extension at 728C for one minute; (2) fibronectin, processed in the standard fashion, and sections were
stained with periodic acid-Schiff. Slices of kidney for36 cycles, denaturation at 958C for one minute, annealing
at 658C for one minute, and extension at 728C for one immunohistochemical staining were fixed in 10% neu-
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tral-buffered formalin and processed in the standard
manner, and 5 micron sections were utilized. Slides were
deparaffinized, hydrated in ethyl alcohol, and washed in
tap water. Antigen retrieval was carried out in 10 mmol/L
sodium citrate buffer for 20 minutes using a Black and
Decker vegetable steamer. For 12-LO staining, a poly-
clonal rabbit antiporcine 12-LO antibody (Dako, Car-
pinteria, CA, USA) diluted 1:300 with 2% casein in BSA
was applied for overnight incubation at room tempera-
ture. After washing, the secondary swine anti-rabbit anti-
body was added for 20 minutes. Slides were washed and
Fig. 1. Rat mesangial cell (MC) 12 lipoxygenase (12-LO)/GAPDHthen incubated with a tertiary rabbit-PAP complex for
mRNA and fibronectin/GAPDH mRNA ratios after incubation in nor-
20 minutes. Diaminobenzidine was added for seven min- mal (h) or high ( ) glucose media. *P , 0.005 vs. NG.
utes, and slides were counterstained with hematoxylin.
For fibronectin staining, the primary monoclonal mouse
anti-Ec fibronectin antibody (Chemicon, Temecula, CA,
USA) was diluted 1:100 with ChemMate antibody dilu-
tion buffer (Vantana Medical Systems, Tuscon, AZ,
USA) and added for overnight incubation at 48C. The
remainder of the staining procedure was performed with
reagents from and as specified in the ChemMate kit Fig. 2. 12-Lipoxygenase (12-LO) protein expression in normal (NG)
and high (HG) glucose mesangial cells (MC). There was a 2.4-fold(Vantana Medical Systems, Tuscon, AZ, USA).
increase in 12-LO protein expression in HG compared with NG MCsAnimals were given a diabetic nephropathy score
assessed by densitometry (P , 0.05).
based on a 0 to 41 semiquantitative score of glomerular
changes, including mesangial widening, segmental glo-
merulosclerosis, insudative lesions, and capsular drops;
all glomeruli in each section were examined. A semi- After correcting the amount of MC 12-LO and fibronec-
tin mRNA for the amount of GAPDH mRNA, the dif-quantitative score of 0 to 41 was used for assessing
12-LO immunohistochemical staining separately within ferences between the two groups remained significant
(Fig. 1).glomeruli assessing all glomeruli in the sections and in
the tubulointerstitium by evaluating 20 consecutive fields 12-LO protein expression in mesangial cells exposed
to HG. 12-LO protein expression was significantlyusing a 320 objective.
higher in HG than NG MC. There was a 2.4-fold increase
Statistical analysis in 12-LO protein expression in HG compared with NG
cells assessed by densitometry (P , 0.05; Fig. 2).All values are expressed as the mean 6 SEM. Statisti-
cal analysis was performed using the statistical package
Animal studiesSPSS for Windows Version 7.51 (SPSS, Inc., Chicago,
IL, USA). Results were analyzed using Student t test or Animal data. The mean blood glucose levels of C,
DM 1 I, and DM rats were 102.4 6 1.8, 294.2 6 8.9,Kruskal–Wallis nonparametric test for multiple compari-
sons. If there was a significant difference by Kruskal– and 415.0 6 9.2 mg/dL, respectively (P , 0.01). Com-
pared with the C group (4.59 6 1.42 mg/day), 24-hourWallis test, it was further confirmed by Mann–Whitney
U test. urinary albumin excretion was significantly greater in
the DM 1 I (17.84 6 5.79 mg/day, P 5 0.05) and the
DM (22.08 6 4.94 mg/day, P , 0.01) groups at four
RESULTS
months. All animals gained weight over the four-month
Mesangial cell culture studies experiment, but weight gain was highest in C rats, inter-
mediate in DM 1 I, and least in DM (P , 0.01). TheQuantitative competitive RT-PCR. The 12-LO mRNA
of MCs exposed to HG (12.71 6 1.17 attm/mL) was sig- mean body weight after four months was 631.9 6 15.1 g
in the C, 495.6 6 14.0 g in the DM 1 I, and 368.9 6nificantly higher than that of MCs in NG media (6.71 6
0.78 attm/mL, P , 0.005). Fibronectin mRNA was also 9.5 g in the DM group. Kidney weight was measured in
16 rats at the time of sacrifice. The ratio of kidney weightsignificantly higher in HG than NG cells (3.51 6 0.35 vs.
2.21 6 0.10 attm/ng RNA, P , 0.005). On the other to body weight in DM rats (0.87 6 0.04) was significantly
higher than C (0.36 6 0.01) and DM 1 I rats (0.54 6hand, there was no significant difference in the amount
of GAPDH mRNA between the two groups (NG, 3.76 6 0.04, P , 0.01; Table 1).
Quantitative competitive RT-PCR. Glomerular 12-LO0.29 attm/ng RNA; HG, 3.41 6 0.20 attm/ng RNA).
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Table 1. Body weight, food intakes, kidney weight/body weight, blood glucose, and 24-hour urinary albumin excretion of the three groups
Control DM 1 I DM
(N 5 8) (N 5 8) (N 5 14)
Body weight after 4 months g 631.9615.1 495.6614.0a 368.969.5a,b
Blood glucose mg/dL 102.465.0 294.2625.0a 415.0634.3a,b
24-hour urinary albumin excretion mg/day 4.5961.42 17.8465.79c 22.0864.94a
Kidney weight/body weight 0.3660.01 0.5460.04 0.8760.04a,b
(N 5 4) (N 5 4) (N 5 8)
a P , 0.01 vs. control
b P , 0.01 vs. insulin-treated diabetes (DM 1 I)
c P 5 0.05 vs. control
Fig. 4. Glomerular 12-LO/GAPDH mRNA ratios of the three groups.
The amount of glomerular 12-LO mRNA was corrected by the amountFig. 3. A representative glomerular 12-LO RT-PCR electrophoresis
of glomerular GAPDH mRNA. There was a 3.3-fold increase in glomer-of one control and one diabetic rat. Glomeruli were microdissected,
ular 12-LO mRNA expression in untreated diabetic rats (N 5 14)and competitive RT-PCR was performed at four months after injection
compared with control rats (N 5 8), while insulin-treated rats (N 5 8)of diluent or streptozotocin, respectively. Each lane represents a com-
were intermediate. *P , 0.01 vs. control.petitive RT-PCR reaction (42 cycles) with a fixed amount of 12-LO
wild-type cDNA (312 bp) from the equivalent of 0.5 glomeruli and a
variable amount of 12-LO competitor cDNA (281 bp) as follows: (lane
1) 5 3 1023 attm/mL, (lane 2) 1023 attm/mL, (lane 3) 5 3 1024 attm/mL,
(lane 4) 1024 attm/mL, (lane 5) 5 3 1025 attm/mL, and (lane 6) 1025
attm/mL.
mRNA was significantly higher (over 4-fold) in the DM
group (1.78 6 0.65 3 1023 attm/glomerulus) than the C
group (0.34 6 0.12 3 1023 attm/glomerulus, P , 0.005),
while the amount in the DM 1 I was intermediate (1.28 6
0.50 3 1023 attm/glomerulus; Fig. 3). Glomerular fibro-
Fig. 5. Glomerular fibronectin/GAPDH mRNA ratios of the threenectin mRNA was also significantly higher in DM than groups. The amount of glomerular fibronectin mRNA was corrected
C rats (5.65 6 0.81 3 1022 vs. 2.50 6 0.78 3 1022 attm/ by the amount of glomerular GAPDH mRNA. There was a 2.1-fold
increase in glomerular fibronectin mRNA levels in untreated diabeticglomerulus, P , 0.01), and that in DM 1 I was intermedi-
rats (N 5 14) compared with control (N 5 8), while insulin-treated ratsate (4.29 6 0.71 3 1022 attm/glomerulus). There was (N 5 8) were intermediate. *P , 0.01 vs. control.
no significant difference in the amount of glomerular
GAPDH mRNA among the three groups (C, 1.38 6
0.28 attm/glomerulus; DM 1 I, 2.36 6 0.53 attm/glomeru-
4.51 6 2.17 3 1022 attm/mL; DM 1 I, 2.09 6 0.52 3lus; and DM, 2.04 6 0.33 attm/glomerulus). Even when
1022 attm/mL; and DM, 3.45 6 1.88 3 1022 attm/mL; (2)corrected for GAPDH mRNA, glomerular 12-LO and
fibronectin: C, 2.05 6 0.87 3 1023 attm/mL; DM 1 I,fibronectin mRNA remained significantly higher in DM
1.02 6 0.26 3 1023 attm/mL; and DM, 2.06 6 0.64 3compared with C (12-LO/GAPDH, 0.99 6 0.31 3 1023
1023 attm/mL; and (3) GAPDH: C, 2.88 6 0.82 attm/mL;vs. 0.30 6 0.13 3 1023, DM vs. C, P , 0.01; fibronectin/
DM 1 I, 1.89 6 0.22 attm/mL; and DM, 2.59 6 0.50GAPDH, 3.44 6 0.60 3 1022 vs. 1.67 6 0.19 3 1022, DM
attm/mL. After correcting the amount of tubulointersti-vs. C, P , 0.05; Figs. 4 and 5).
tial 12-LO and fibronectin mRNA for the controlIn contrast to the results in the glomerulus, tubuloin-
GAPDH mRNA, the values in the three groups wereterstitial 12-LO, fibronectin, and GAPDH, mRNA levels
did not differ among the three groups: (1) 12-LO: C, nearly identical (data not shown).
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Fig. 6. A representative 12-LO Western blot of three control and three
untreated diabetic rats. Densitometric quantitation revealed that there
was a 2.8-fold increase in 12-LO protein expression in untreated diabetic
rats compared with control rats (P , 0.05).
Fig. 9. Immunohistochemical score for glomerular 12-LO. The score
was assessed semiquantitatively by the distribution and intensity of
immunohistochemical staining. The score was significantly higher in
diabetic rats (both untreated and insulin-treated) than control rats.
*P , 0.05 vs. control.
staining was performed in DM and C groups only. C
kidneys had no discernible fibronectin staining within
glomeruli, while the DM animals had heavy staining
within mesangial regions (Fig. 10), confirming the mRNA
findings.
Fig. 8. Diabetic nephropathy score of the three groups. The score was
determined semiquantitatively based on glomerular changes including
mesangial widening, segmental glomerulosclerosis, insudative lesions,
DISCUSSIONand capsular drops assessed by light microscopy. The score was signifi-
cantly higher in the untreated diabetic group than the control and The 12-LO pathway has been shown to play a key
insulin-treated groups. *P , 0.001 vs. control; #P , 0.05 vs. insulin-
role in the actions of effector molecules such as glucose,treated diabetic group.
angiotensin II, and platelet-derived growth factor in vas-
cular smooth muscle cells [13, 14, 16]. Our study demon-
strates for the first time, to our knowledge, that glucose
12-Lipoxygenase protein expression in diabetic kidney stimulates MC 12-LO mRNA and protein synthesis and
that glomerular 12-LO mRNA and protein expressionFigure 6 is a representative Western blot showing ex-
are increased in experimental diabetic nephropathy, sug-pression of glomerular 12-LO protein in C and DM rats.
gesting a potential role of this pathway in the mediation12-LO protein expression was higher in DM than C rats.
of experimental diabetic nephropathy.Densitometric quantitation revealed that there was a
Mesangial cells in vitro predominantly synthesize2.8-fold increase in 12-LO protein expression in DM
12-LO [19], and to a lesser extent, 15- or 5-LO productscompared with C rats (P , 0.05).
(abstract; Imai et al, J Am Soc Nephrol 1:751, 1990). In
Pathology addition, urinary 12-HETE excretion is markedly in-
creased in diabetic patients with or without microalbumin-The DM group had diffuse expansion of mesangial
regions with occasional glomerular segmental sclerosis uria compared with healthy controls, suggesting a renal
origin [30]. Thromboxane A2 and 5-LO products origi-and insudates, and infrequent capsular drops resulting
in a diabetic nephropathy score (1.17 6 0.13) that was nating from infiltrating inflammatory cells have been
shown to be increased in studies of experimental glomer-significantly higher than the C (0.21 6 0.10, P , 0.001)
and DM 1 I (0.56 6 0.15, P , 0.05) groups (Figs. 7 and ulonephritis and to mediate the decrements in glomeru-
lar filtration rate and renal blood flow which accompany8). Immunohistochemical staining for glomerular 12-LO
confirmed the mRNA and Western blot findings. Glo- MC immune injury [17, 18, 31, 32]. However, in contrast
to immune-mediated glomerular disease, there is littlemerular 12-LO appeared to be both within mesangial
and visceral epithelial cells and by semiquantitative scor- cellular infiltration in diabetic nephropathy. Therefore,
this study focused on 12-LO rather than other LOs. Theing was significantly higher in DM (0.79 6 0.11) and
DM 1 I rats (0.53 6 0.03) compared with C rats (0.29 6 ability of high-glucose medium concentration to stimulate
MC 12-LO delineates at least one mechanism whereby0.14, P , 0.05; Figs. 7 and 9). There was patchy staining of
tubular epithelial cells within proximal and distal tubules the diabetic milieu might induce glomerular 12-LO in
vivo. Thus, the data support the hypothesis that glomeru-that did not reach statistical significance (C, 0.61 1 0.24;
DM 1 I, 0.72 1 0.13; and DM, 0.90 1 0.16). Transitional lar 12-LO may contribute to the development of diabetic
nephropathy.epithelium in the renal pelvis stained strongly for 12-LO
in all three groups (data not shown). Fibronectin Ec Numerous in vitro studies in nonrenal cells suggest
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Fig. 7. Glomeruli from the untreated dia-
betic group (A and D) and the insulin-treated
group (B and E). Mesangial regions in the
untreated diabetic group are expanded with
period acid-Schiff–positive material without
hypercellularity (A). There are 12-LO–positive
cells in mesangial regions and along capillary
walls (D). There is mild mesangial expansion
in the insulin-treated group (B), that is less
than in the untreated diabetic group. There is
weak staining for 12-LO (E). (C and F ) Con-
trol group glomeruli. Mesangial regions have
the normal width (C). There is no staining of
any cells for 12-LO (F). (A–C) Periodic acid-
Schiff 3 260. (D–F) 12-LO 3260.
acid and its metabolites stimulated mitogen-activated
protein kinase (MAP-kinase) activity in vascular smooth
muscle cells [36] and 12-HETE led to sustained activa-
tion of MAP-kinases including c-Jun N-amino terminal
kinase (JNK) [37, 38]. LO activation can directly lead
to oxidant stress by the generation of superoxide [39],
and this may mediate cell injury/nephropathy since oxi-
dant stress plays a key role in diabetic complications [40].
12-HETE, angiotensin II, and a high ambient glucose
concentration stimulate fibronectin synthesis in vascular
smooth muscle cells [13, 16]. Finally, LO inhibitors could
block angiotensin II-induced vascular smooth muscle cell
hypertrophy [16]. Thus, the 12-LO pathway could poten-
tially mediate the glomerular changes of diabetic ne-
phropathy through numerous mechanistic pathways.
In contrast to the results with glomerular samples,
there was no difference in tubulointerstitial 12-LO, fi-
bronectin, or GAPDH mRNA, and the immunohisto-
chemical staining for 12-LO and fibronectin was similar
among the three experimental groups. By immunohisto-
chemistry, 12-LO protein showed focal and patchy distri-Fig. 10. Glomeruli stained for fibronectin-Ec. (A) Untreated diabetic
bution throughout the tubulointerstitium. There was rel-group showing staining within mesangial regions. (B) Control group
without mesangial staining (3300). atively strong staining of 12-LO in the deep medulla and
pelvis, a feature that was consistent in all three groups.
For RNA extraction and RT-PCR of the tubulointersti-
tium, the studied renal tissue included both cortex andpotential pathways by which 12-LO activation might par-
deep medulla. The heavy 12-LO expression in the me-ticipate in the pathogenesis of this disease. These demon-
dulla, as demonstrated by immunohistochemistry, maystrate the role of the 12-LO pathway in regulating key
have obscured more subtle localized tubulointerstitialsignal transducing kinases and the role of 12-LO activa-
changes, thus explaining the discordance between thetion in stimulating fibronectin synthesis. Specifically, the
tubulointerstitial findings and the results in glomerularcapacity of the 12-LO product 12-HETE to activate PKC
samples. It is known that glomerular MCs and tubularis demonstrated in experiments in adrenal glomerulosa
epithelial cells exhibit numerous similar responses undercells, where exogenous provision of 12-HETE led to
high-glucose conditions. For example, high glucose in-PKC translocation from the cytosol to membrane frac-
creases TGF-b1 mRNA and protein in both culturedtion [15]. PKC-g activation by 12-HETE has also been
MCs and proximal tubular cells [41]. High glucose alsodemonstrated in brain cell culture [33]. LO metabolites
increases decorin mRNA expression in cultured mouseof arachidonic acid have been reported to mediate tumor
mesangial and tubular epithelial cells [42]. However,necrosis factor-a–induced protooncogene c-fos expres-
sion [34] and to increase ras activity [35]. Arachidonic 12-LO in tubular epithelial cells has not been studied,
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matrix synthesis and mRNA in mesangial cells grown in high-and it is equally possible that activation in tubular epithe-
glucose medium. Am J Physiol 260:F185–F191, 1991
lial cells may differ from that in MCs. In vitro studies 4. Doi T, Vlassara H, Kirstein M, et al: Receptor-specific increase
in extracellular matrix production in mouse mesangial cells byof 12-LO using tubular epithelial cells will be necessary
advanced glycosylation end products is mediated via platelet-to clarify this question.
derived growth factor. Proc Natl Acad Sci USA 89:2873–2877, 1992
In rabbit tubular epithelial cells, arachidonic acid has 5. Ihm CG, Lee GS, Nast CC, et al: Early increased renal procollagen
a1 (IV) mRNA levels in streptozotocin induced diabetes. Kidneybeen shown to activate JNK by stimulation of nicotin-
Int 41:768–777, 1992amide adenine dinucleotide phosphate (NADPH) oxi-
6. Nahman NS Jr, Leonhart KL, Cosio FG, et al: Effect of high
dase and superoxide generation, independent of eicosa- glucose on cellular proliferation and fibronectin production by
cultured human mesangial cell. Kidney Int 41:396–402, 1992noid biosynthesis [43]. Recently, there was also a report
7. Kitamura M, Kitamura A, Mitarai T, et al: Gene expression ofthat in interleukin-1 (IL-1)-stimulated MCs, only free
metalloproteinase and its inhibitor in mesangial cells exposed to
arachidonic acid and its precursor linoleic acid—but not high glucose. Biochem Biophys Res Commun 185:1048–1054, 1992
8. Phillips AO, Steadman R, Morrisey K, et al: Exposure of humanother fatty acids—stimulated JNK1/stress-activated pro-
renal proximal tubular cells to glucose leads to accumulation oftein kinase (SAPK), and their effects were independent
type IV collagen and fibronectin by decreased degradation. Kidney
of cyclooxygenase, lipoxygenase, and P-450 epoxygenase Int 52:973–984, 1997
9. Bell RL, Kennerly DA, Stanford N, et al: Diglyceride lipase:pathway [44]. Both reports focused only on JNK, but
A pathway for arachidonate release from human platelet. Procthere are numerous signal transduction pathways besides
Natl Acad Sci USA 76:3238–3241, 1979
those involving JNK that could mediate the pathogenesis 10. Asaoka Y, Nakamura S, Yoshida K, et al: Protein kinase C,
calcium and phospholipid degradation. Trends Biochem Sci 17:414–of diabetic glomerulopathy. Because the former study
417, 1992was performed using tubular epithelial cells, there is a
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possibility that tubular cells may respond differently action. Biochem J 259:315–324, 1989
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sensitization. J Biol Chem 265:19973–19979, 1990
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1993
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